To characterize the pharmacokinetics ( PK ) and pharmacodynamics ( PD ) of a new insulin glargine comprising 300 units mL ( -1 ) ( Gla-300 ) , compared with insulin glargine 100 units mL ( -1 ) ( Gla-100 ) at steady state in people with type 1 diabetes .